May 5, 2020 / 11:05 AM / a month ago

BRIEF-Vifor Pharma: Akebia Reports Positive Top-Line Results From Inno(2)Vate

May 5 (Reuters) - VIFOR PHARMA AG:

* VIFOR PHARMA ANNOUNCES AKEBIA’S POSITIVE TOP-LINE RESULTS FROM GLOBAL PHASE-III PROGRAM OF VADADUSTAT FOR TREATMENT OF ANAEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULT DIALYSIS-DEPENDENT PATIENTS

* ANNOUNCED THAT ITS PARTNER, AKEBIA THERAPEUTICS, TODAY REPORTED POSITIVE TOP-LINE RESULTS FROM INNO(2)VATE, AKEBIA’S GLOBAL PHASE-III CARDIOVASCULAR OUTCOMES PROGRAM

* AKEBIA PLANS TO SUBMIT NDA FOR VADADUSTAT FOR TREATMENT OF ANEMIA DUE TO CKD IN DIALYSIS DEPENDENT AND NON-DIALYSIS DEPENDENT PATIENTS TO FDA Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below